2024
Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes
McCoy R, Swarna K, Deng Y, Herrin J, Ross J, Kent D, Borah B, Crown W, Montori V, Umpierrez G, Galindo R, Brito J, Mickelson M, Polley E. Derivation of an Annualized Claims-Based Major Adverse Cardiovascular Event Estimator in Type 2 Diabetes. JACC Advances 2024, 3: 100852. PMID: 38939660, PMCID: PMC11198625, DOI: 10.1016/j.jacadv.2024.100852.Peer-Reviewed Original ResearchType 2 diabetesMedicare fee-for-service planClaims-based prediction modelPopulation risk stratificationRisk of Major Adverse Cardiovascular EventsMajor adverse cardiovascular eventsNon-Hispanic whitesFee-for-service plansStudy cohortClinical trials of cardiovascular diseaseCox proportional hazards modelsProportional hazards modelCare populationHealth systemPrimary preventionMedicare AdvantageParticipant identificationPayer levelPharmacy claimsDecentralized clinical trialsHazards modelCardiovascular diseaseRisk predictionMedicarePatient population
2021
Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases
Singh S, Heien HC, Herrin J, Dulai PS, Sangaralingham L, Shah ND, Sandborn WJ. Comparative Risk of Serious Infections With Tumor Necrosis Factor α Antagonists vs Vedolizumab in Patients With Inflammatory Bowel Diseases. Clinical Gastroenterology And Hepatology 2021, 20: e74-e88. PMID: 33640480, PMCID: PMC8384969, DOI: 10.1016/j.cgh.2021.02.032.Peer-Reviewed Original ResearchConceptsInflammatory bowel diseaseSerious infectionsMarginal structural Cox proportional hazards modelsCox proportional hazards modelBaseline disease characteristicsRetrospective cohort studyAdministrative claims databaseProportional hazards modelTime-varying useCohort studyBowel diseaseTreatment initiationUlcerative colitisHealthcare utilizationClaims databaseDisease characteristicsTumor necrosisVedolizumabLower riskHazards modelPatientsInfectionAntagonistInsurance coverageRisk
2020
Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention
Abraham NS, Yang EH, Noseworthy PA, Inselman J, Yao X, Herrin J, Sangaralingham LR, Ngufor C, Shah ND. Fewer gastrointestinal bleeds with ticagrelor and prasugrel compared with clopidogrel in patients with acute coronary syndrome following percutaneous coronary intervention. Alimentary Pharmacology & Therapeutics 2020, 52: 646-654. PMID: 32657466, PMCID: PMC8183594, DOI: 10.1111/apt.15790.Peer-Reviewed Original ResearchMeSH KeywordsAcute Coronary SyndromeAgedClopidogrelCohort StudiesFemaleGastrointestinal HemorrhageHumansMaleMiddle AgedPercutaneous Coronary InterventionPlatelet Aggregation InhibitorsPostoperative ComplicationsPrasugrel HydrochlorideRetrospective StudiesThromboembolismTicagrelorTreatment OutcomeUnited StatesConceptsPercutaneous coronary interventionAcute coronary syndromeGIB ratesGIB riskCoronary syndromeGastrointestinal bleedingSTEMI patientsCoronary interventionHazard ratioMajor adverse cardiac eventsRisk reductionCox proportional hazards modelNSTE-ACS patientsAdverse cardiac eventsMajor bleeding eventsConfidence intervalsInverse probability treatmentProportional hazards modelMedicare Advantage enrolleesBleeding eventsClopidogrel prescriptionGIB eventsNSTE-ACSGastrointestinal bleedBaseline characteristics
2013
Immediate Open Repair vs Surveillance in Patients with Small Abdominal Aortic Aneurysms: Survival Differences by Aneurysm Size
Filardo G, Lederle FA, Ballard DJ, Hamilton C, da Graca B, Herrin J, Harbor J, VanBuskirk JB, Johnson GR, Powell JT. Immediate Open Repair vs Surveillance in Patients with Small Abdominal Aortic Aneurysms: Survival Differences by Aneurysm Size. Mayo Clinic Proceedings 2013, 88: 910-919. PMID: 24001483, DOI: 10.1016/j.mayocp.2013.05.014.Peer-Reviewed Original ResearchConceptsImmediate open repairAbdominal aortic aneurysmOpen repairSurvival differencesAAA sizeSurvival benefitAortic aneurysmUK Small Aneurysm TrialAsymptomatic abdominal aortic aneurysmLarge abdominal aortic aneurysmSmall asymptomatic abdominal aortic aneurysmsSmall abdominal aortic aneurysmsImmediate endovascular repairNonclinical risk factorsSignificant survival benefitFirst-line managementSignificant survival differenceProportional hazards modelEndovascular repairSurveillance patientsAdjusted analysisStudy cohortAneurysm TrialRecent trialsRisk factors